The involvement of cytochrome P450 3A4 in the N-demethylation of L- α-acetylmethadol (LAAM), norlaam, and methadone

Drug Metabolism and Disposition

Volumn 25, Issue 12, 1997, Pages 1347-1353

  Moody, David E ^b   Alburges, Mario E ^b   Parker, Robert J ^b   Collins, Jerry M ^b   Strong, John M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; KETOCONAZOLE; LIVER ENZYME; METHADONE; OPIATE;

ARTICLE; DEMETHYLATION; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; MAINTENANCE THERAPY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS;

CYTOCHROME P-450 ENZYME SYSTEM; DIMETHYLAMINES; DNA, COMPLEMENTARY; ENZYME INHIBITORS; HUMANS; ISOENZYMES; METHADONE; METHADYL ACETATE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; SUBSTRATE SPECIFICITY;

EID: 0031448854     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. V. P. Dole: Implications of methadone maintenance for therapies of narcotic addiction: The Albert Lasker Awards. JAMA 260, 3025-3029 (1988).
2. M. Farrell, J. Ward, R. Mattrick, W. Hall, G. V. Stimson, D. des Jarlais, M. Gossop, and J. Strang: Methadone maintenance treatment in opiate dependence: a review. Br. Med. J. 309, 997-1001 (1994).
3. J. H. Jaffe, E. C. Senay, C. R. Schuster, P. R. Renault, B. Smith, and S. DiMenza: Methadyl acetate vs. methadone: a double-blind study in heroin users. JAMA 222, 437-442 (1972).
4. R. Levine, A. Zaks, M. Fink, and M. Freedman: Levomethadyl acetate: prolonged duration of opioid effects, including cross tolerance to heroin, in man. JAMA 226, 316-318 (1973).
5. W. Ling, C. Charuvastra, S. C. Kaim, and J. Klett: Methadyl acetate and methadone as maintenance treatments for heroin addicts. Arch. Gen. Psychiatry 33, 709-720 (1976).
6. The Medical Letter: LAAM: a long-acting methadone for treatment of heroin addiction. Med. Lett. 36, 52 (1994).
7. A. H. Beckett, J. F. Taylor, A. F. Casy, and M. M. A. Hassan: The biotransformation of methadone in man: synthesis and identification of a major metabolite. J. Pharm. Pharmacol. 20, 754-762 (1968).
8. A. Pohland, H. E. Boaz, and H. R. Sullivan: Synthesis and identification of metabolites resulting from the biotransformation of dl-methadone in man and in the rat. J. Med. Chem. 14, 194-197 (1971).
9. R. E. Billings, R. Booher, S. Smits, A. Pohland, and R. E. McMahon: Metabolism of acetylmethadol: a sensitive assay for noracetylmethadol and the identification of a new active metabolite. J. Med. Chem. 16, 305-306 (1973).
10. 3H in nontolerant and tolerant rats. J. Pharmacol. Exp. Ther. 185, 287299 (1973).
11. G. L. Henderson, H. North-Root, and S. H. Kuttab: Metabolism and disposition of 1-α-acetylmethadol in the rat. Drug Metab. Dispos. 5, 321-328 (1977).
12. J. Axelrod: The enzymatic N-demethylation of narcotic drugs. J. Pharmacol. Exp. Ther. 117, 322-330 (1956).
13. R. E. McMahon, H. W. Culp, and F. J. Marshall: The metabolism of α-dl-acetylmethadol in the rat: the identification of the probable active metabolite. J. Pharmacol. Exp. Ther. 149, 436-445 (1965).
14. L. W. Masten, G. R. Peterson, A. Burkhalter, and E. L. Way: Effect of oral administration of methadone on hepatic microsomal mixed function oxidase activity in mice. Life Sci. (Washington, D.C.) 14, 1635-1640 (1974).
15. N. Gerber, R. M. Leger, P. Gordon, R. G. Smith, J. Bauer, and R. K. Lynn: The metabolism of d-, l- and dl-methadone in the isolated perfused rat liver. J. Pharmacol. Exp. Ther. 200, 487-495 (1977).
16. R. E. Billings, R. E. McMahon, J. Ashmore, and S. R. Wagle: The metabolism of drugs in isolated hepatocytes: a comparison with in vivo drug metabolism and drug metabolism in subcellular liver fractions. Drug Metab. Dispos. 5, 518-526 (1977).
17. M. J. Kreek: Hepatic extraction of long- and short-acting narcotics in the isolated perfused rabbit liver. Gastroenterology 75, 88-94 (1978).
18. L. W. Masten, S. R. Price, and C. J. Burnett: Microsomal enzyme induction following repeated oral administration of LAAM. Res. Commun. Chem. Pathol. Pharmacol. 20, 1-20 (1978).
19. S. M. Roberts and M. R. Franklin: Modification of hepatic microsomal oxidative drug metabolism in rats by the opiate maintenance drugs acetylmethadol, propoxyphene, and methadone. Life Sci. (Washington, D.C.) 25, 845-852 (1979).
20. D. E. Moody, D. J. Crouch, C. O. Sakashita, M. E. Alburges, K. Minear, J. E. Schulthies, and R. L. Foltz: A gas chromatographic-positive ion chemical ionization-mass spectrometric method for determination of 1-α-acetylmethadol (LAAM), norLAAM. and dinorLAAM in plasma, urine, and tissue. J. Anal. Toxicol. 19, 343-351 (1995).
21. C. Iribarne, F. Berthou, S. Baird, Y. Dreano, D. Picart, J. P. Bail, P. Beaune, and J. F. Menez: Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. 9, 365-373 (1996).
22. M. E. Alburges, W. Huang, R. L. Foltz, and D. E. Moody: Determination of methadone and its N-demethylation metabolites in biological specimens by gas chromatography/positive ion chemical ionization-mass spectrometry. J. Anal. Toxicol. 20, 362-368 (1996).
23. H. R. Sullivan and S. L. Due: Urinary metabolites of d,l-methadone in maintenance subjects. J. Med. Chem. 16, 909-913 (1973).
24. A. Pohland, F. J. Marshall, and T. P. Carney: Optically active compounds related to methadone. J. Am. Chem. Soc. 71, 460-462 (1949).
25. J. S. Horng, S. E. Smits, and D. T. Wong: The binding of optical isomers of methadone, α-acetylmethadol and their N-demethylated derivatives to the opiate receptors of rat brain. Res. Commun. Chem. Pathol. Pharmacol. 14, 621-629 (1976).
26. S. A. Walczak, M. H. Makman, and E. L. Gardner: Acetylmethadol metabolites influence opiate receptors and adenylate cyclase in amygdala. Eur. J. Pharmacol. 72, 343-349 (1981).
27. R. F. Kaiko and C. E. Inturrisi: Disposition of acetylmethadol in relation to pharmacologic action. Clin. Pharmacol. Ther. 18, 96-103 (1975).
28. C. C. Peck, R. Temple, and J. M. Collins: Understanding consequences of concurrent therapy. JAMA 269, 1550-1552 (1993).
29. C. V. Grudzinskas, R. L. Woosley, T. J. Payte, J. Collins, D. E. Moody, R. F. Tyndale, and E. M. Sellers: The documented role of pharmacogenetics in the identification and administration of new medications for treating drug abuse. NIDA Res. Monogr. 162, 60-61 (1996).
30. M. J. Kreek, J. W. Garfield, C. L. Gutjahr, and L. M. Giusti: Rifampin-induced methadone withdrawal. N. Engl. J. Med. 294, 1104-1106 (1976).
31. J. W. Harris, A. Rahman, B.-K. Kim, F. P. Guengerich, and J. M. Collins: Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54, 4026-4035 (1994).
32. M. M. Bradford: A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal. Biochem. 72, 248-254 (1976).
33. T. Omura and R. Sato: The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378 (1964).
34. J. H. Zar: "Biostatistical Analysis." Prentice Hall, Englewood Cliffs, NJ, 1984.
35. U. Fuhr, T. Wolff, S. Harder, P. Schymanski, and A. H. Staib: Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metab. Dispos. 18, 1005-1010 (1990).
36. S. J. Baldwin, J. C. Bloomer, G. J. Smith, A. D. Ayrton, S. E. Clarke, and R. J. Chenery: Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25, 261-270 (1995).
37. D. J. Newton, R. W. Wang, and A. Y. H. Lu: Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
38. A. Parkinson: Biotransformation of xenobiotics. In "Casarett & Doull's Toxicology: The Basic Science of Poisons" (C.D. Klaassen, ed.), pp. 113-186. 5th Edition, McGraw-Hill, Inc., New York, 1996.
39. A. E. Robinson and F. M. Williams: The distribution of methadone in man. J. Pharm. Pharmacol. 23, 353-358 (1971).
40. C. E. Inturrisi and K. Verebely: Disposition of methadone in man after a single oral dose. Clin. Pharmacol. Ther. 13, 923-930 (1972).
41. B. S. Finkle, T. A. Jennison, D. M. Chinn, W. Ling, and E. D. Holmes: Plasma and urine disposition of 1-α-acetylmethadol and its principal metabolites in man. J. Anal. Toxicol. 6, 100-105 (1982).
42. P. B. Watkins: Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4, 171-184 (1994).
43. T. A. Ketter, D. A. Flockhart, R. M. Post, K. Denicoff, P. J. Pazzaglia, L. B. Marangell, M. S. George, and A. M. Callahan: The emerging role of cytochrome P450 3A in psychopharmacology. J. Clin. Psychopharmacol. 15, 387-398 (1995).
44. A. P. Li, D. L. Kaminski, and A. Rasmussen: Substrates of human hepatic cytochrome P450 3A4. Toxicology 104, 1-8 (1995).
45. S. A. Wrighton, B. J. Ring, and M: Vanden Branden: The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Toxicol. Path. 23, 199-208 (1995).
46. S.-J. Liu, and R. I. H. Wang: Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome. Am. J. Psychiatry 141, 1287-1288 (1984).
47. T. G. Tong, S. M. Pond, M. J. Kreek, N. F. Jaffery, and N. L. Benowitz: Phenytoin-induced methadone withdrawal. Ann. Intern. Med. 94, 349-351 (1981).
48. L. Pichard, I. Fabre, G. Fabre, J. Domergue, B. Saint Aubert, G. Mourad, and P. Maurel: Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18, 595-606 (1990).
49. G. Bertschy, P. Baumann, C. B. Eap, and D. Baettig: Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther. Drug Monit. 16, 42-45 (1994).
50. E. Skjelbo and K. Brosen: Inhibitors of imipramine metabolism by human liver microsomes. Br. J. Clin. Pharmacol. 34, 256-261 (1992).
51. K. Brosen, E. Skjelbo, B. B. Rasmussen, H. E. Poulsen, and S. Loft: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45, 1211-1214 (1993).
52. L. L. von Moltke, D. J. Greenblatt, M. H. Court, S. X. Duan, J. S. Harmatz, and R. I. Shader: Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J. Clin. Psychopharmacol. 15, 125-131 (1995).
53. J. Schmider, D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, and R. I. Shader: N-Demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J. Pharmacol. Exp. Ther. 275, 592-597 (1995).
54. D. R. Nelson, L. Koymans, T. Kamataki, J. J. Stegeman, R. Feyereisen, D. J. Waxman, M. R. Waterman, O. Gotoh, M. J. Coon, R. W. Estabrook, I. C. Gunsalus, and D. W. Nebert: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1-42 (1996).